Table 4. miRNAs with relative expression level associated with poor prognosis, their function and target or related gene.
| miRNA | Expression level associate with poor prognosis | Function | Target or related gene |
|---|---|---|---|
| miR-210[10] | high | Oncogene (Tumor Initiation) | N/D |
| miR-17–92[19] | high | Oncogene (Tumor Progression) | N/D |
| miR-128[23] | high | Oncogene | Inhibits PTEN |
| miR-9[27] | high | Oncogene Promote metastasis | N/D |
| miR-214[26] | high | Oncogene (Tumor Progression) | N/D |
| miR-542-5p [14] | high | Oncogene | Inhibits HUWE1 |
| miR-130b [29] | high | Oncogene (Tumor Progression) | Inhibits PPARγ |
| miR-130a [12] | high | Oncogene Promote metastasis | Inhibits PTEN |
| miR-199b-5p [31] | high | Oncogene | HES1 |
| miR-132 [28] | low | Discriminate good responders from poor responders | N/D |
| miR-145 [22] | low | Tumor suppressor Discriminate good responders from poor responders | N/D |
| miR-382 [20] | low | Oncogene Suppress metastasis | Stabilize MYC |
| miR-133a [18] | low | Tumor suppressor Suppress pulmonary metastasis | Inhibits Bcl-xL, Mcl-1 |
| miR-26a [21] | low | Tumor suppressor Suppress metastasis and recurrence | Inhibits EZH2 |
| miR-340 [11] | low | Tumor suppressor Suppress metastasis | N/D |
| miR-20a [9] | low | Tumor suppressor | Inhibits FAS |
| miR-92a [9] | low | Discriminate ifosfamide responder | Inhibits FAS |
| miR-143 [33] | low | Tumor suppressor Suppress pulmonary metastasis | MMP-13 Bcl-2 |
| miR-451 [30] | low | Tumor suppressor | N/D |
| miR-144 [25] | low | Tumor suppressor Suppress metastasis | Inhibits ROCK1, ROCK2 |
| miR-22 [24] | low | Tumor suppressor | Inhibits HMGB1 |
| miR-195 [17] | low | Suppress metastasis | Inhibits CCND1 |
| miR-124 [16] | low | Tumor suppressor | N/D |
| miR-449a [13] | low | Tumor suppressor | Inhibits Bcl-2 |
| miR-99a [32] | low | Tumor suppressor | mTOR |
| miR-224 [15] | Low | Tumor suppressor | Rac1 |
- N/D, not determined; PTEN, phosphatase and tensin homolog; HUWE1; PPARγ, peroxisome proliferator-activated receptor gamma; HES1, hes family bHLH transcription factor 1; MYC, v-myc avian myelocytomatosis viral oncogene homolog ; Bcl-xL, BCL2-like 1 isoform 1; Mcl-1, BCL2 family apoptosis regulator; EZH2, enhancer of zeste 2 polycomb repressive complex 2 subunit; FAS, tumor necrosis factor receptor superfamily member 6; MMP-13, matrix metallopeptidase 13; Bcl-2, B-cell lymphoma 2; ROCK, Rho-associated protein kinase; HMGB1, high mobility group box 1; CCND1, Cyclin D1; MTOR, mechanistic target of rapamycin; Rac1, Ras-related C3 botulinum toxin substrate 1